Search

Your search keyword '"Calareso, G"' showing total 274 results
Start Over Author "Calareso, G"
274 results on '"Calareso, G"'

1. Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)

Author

Proto, C., Ganzinelli, M., Manglaviti, S., Imbimbo, M., Galli, G., Marabese, M., Zollo, F., Alvisi, M.F., Perrino, M., Cordua, N., Borea, F., de Vincenzo, F., Chella, A., Cappelli, S., Pardini, E., Ballatore, Z., Lucarelli, A., Ambrosini, E., Giuliano, M., Pietroluongo, E., Mulargiu, C., Fabbri, A., Prelaj, A., Occhipinti, M., Brambilla, M., Mazzeo, L., Beninato, T., Vigorito, R., Ruggirello, M., Greco, F.G., Calareso, G., Miliziano, D., Rulli, E., De Simone, I., Torri, V., de Braud, F.G.M., Pasello, G., De Placido, P., Berardi, R., Petrini, I., Zucali, P., Garassino, M.C., and Lo Russo, G.

Published
2024
Full Text
View/download PDF

3. T-Staging and Target Volume Definition by Imaging in GYN Tumors

Author

Alessi, A., Pappalardi, B., Cerrotta, A., Calareso, G., Crippa, F., Kauczor, Hans-Ulrich, Series Editor, Parizel, Paul M., Series Editor, Peh, Wilfred C. G., Series Editor, Brady, Luther W., Honorary Editor, Lu, Jiade J., Series Editor, Beets-Tan, Regina G.H., editor, Oyen, Wim J. G., editor, and Valentini, Vincenzo, editor

Published
2020
Full Text
View/download PDF

5. 27P Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab (DURVA): Preliminary analysis from the phase II ARCADIA trial

Author

Sgambelluri, F., primary, Giannatempo, P., additional, Stellato, M., additional, Guadalupi, V., additional, Raggi, D., additional, Bottiglieri, A., additional, Claps, M., additional, Ferrari Bravo, W., additional, Oldani, S., additional, Zimatore, M., additional, Calareso, G., additional, Alessi, A., additional, Cattaneo, L., additional, Verzoni, E., additional, De Braud, F.G.M., additional, Procopio, G., additional, Necchi, A., additional, Anichini, A., additional, and Mortarini, R., additional

Published
2023
Full Text
View/download PDF

6. 26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)

Author

Huber, V., primary, Mereu, A., additional, Lalli, L., additional, Salsetta, J., additional, Banfi, C., additional, Squarcina, P., additional, Sgambelluri, F., additional, Mortarini, R., additional, Stellato, M., additional, Raggi, D., additional, Guadalupi, V., additional, Claps, M., additional, Ferrari Bravo, W., additional, Calareso, G., additional, Alessi, A., additional, Anichini, A., additional, Procopio, G., additional, Necchi, A., additional, Rivoltini, L., additional, and Giannatempo, P., additional

Published
2023
Full Text
View/download PDF

7. OP12.05: Patient satisfaction with ultrasound, CT and WB‐DWI/MRI for preoperative ovarian cancer staging: a multicentre prospective survey

Author

Pinto, P., primary, Borcinova, M., additional, Wiesnerova, M., additional, Frühauf, F., additional, Burgetova, A., additional, Mašek, M., additional, Lambert, L., additional, Chiappa, V., additional, Franchi, D., additional, Testa, A. C., additional, Moro, F., additional, Avesani, G., additional, Panico, C., additional, Alessi, S., additional, Pricolo, P., additional, Vigorito, R., additional, Calareso, G., additional, Kocian, R., additional, Slama, J., additional, Fagotti, A., additional, Urbinati, A. M. Vidal, additional, Signorelli, M., additional, Valentin, L., additional, Cibula, D., additional, and Fischerová, D., additional

Published
2023
Full Text
View/download PDF

8. 2370P Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)

Author

Bottiglieri, A., primary, Ferrari Bravo, W., additional, Rametta, A., additional, Provenzano, L., additional, Raggi, D., additional, Marandino, L., additional, Farè, E., additional, Longo, V., additional, Guadalupi, V., additional, Stellato, M., additional, Verzoni, E., additional, Sepe, P., additional, Claps, M., additional, Calareso, G., additional, Alessi, A., additional, Cattaneo, L., additional, Colecchia, M., additional, Procopio, G., additional, Necchi, A., additional, and Giannatempo, P., additional

Published
2023
Full Text
View/download PDF

11. 25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils

Author

Ferrara, R., primary, Lo Russo, G., additional, Ciniselli, C.M., additional, Bassani, B., additional, Calareso, G., additional, Duroni, V., additional, Di Gregorio, S., additional, Proto, C., additional, Prelaj, A., additional, De Toma, A., additional, Occhipinti, M., additional, Brambilla, M., additional, Manglaviti, S., additional, Mazzeo, L., additional, Ganzinelli, M., additional, De Braud, F.G.M., additional, Garassino, M.C., additional, Colombo, M.P., additional, Verderio, P., additional, and Sangaletti, S., additional

Published
2022
Full Text
View/download PDF

13. 1057P Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations

Author

Ferrara, R., primary, Lo Russo, G., additional, Ciniselli, C.M., additional, Di Gregorio, S., additional, Calareso, G., additional, Bassani, B., additional, Proto, C., additional, Prelaj, A., additional, De Toma, A., additional, Occhipinti, M., additional, Brambilla, M., additional, Manglaviti, S., additional, Mazzeo, L., additional, Beninato, T., additional, Ganzinelli, M., additional, De Braud, F.G.M., additional, Garassino, M.C., additional, Colombo, M.P., additional, Verderio, P., additional, and Sangaletti, S., additional

Published
2022
Full Text
View/download PDF

14. 2014P Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)

Author

Giannatempo, P., Polymeropoulos, A., Stellato, M., Ambrosini, P., Gusmaroli, E., Cavalli, C., Guadalupi, V., Claps, M., Raggi, D., Rametta, A., Ortega, C., Tucci, M., Buti, S., Pipitone, S., Iacovelli, R., Calareso, G., Alessi, A., Procopio, G., Miceli, R., and Necchi, A.

Published
2024
Full Text
View/download PDF

15. 1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis

Author

Stellato, M., Giannatempo, P., Polymeropoulos, A., Guadalupi, V., Claps, M., Ambrosini, P., Raggi, D., Rametta, A., Cavalli, C., Gusmaroli, E., Ortega, C., Tucci, M., Buti, S., Pipitone, S., Iacovelli, R., Calareso, G., Alessi, A., Procopio, G., Miceli, R., and Necchi, A.

Published
2024
Full Text
View/download PDF

16. OC04.03: Preoperative assessment of non‐resectability in ovarian cancer according to ESGO criteria: a prospective multicentre study using imaging (ISAAC study).

Author

Moro, F., Pinto, P., Chiappa, V., Testa, A., Alcazar, J., Franchi, D., Frühauf, F., Burgetova, A., Mašek, M., Lambert, L., Arraiza, M., Altmanova, D., Avesani, G., Panico, C., Alessi, S., Pricolo, P., Vigorito, R., Calareso, G., Kocian, R., and Slama, J.

Subjects
DIFFUSION magnetic resonance imaging, RECEIVER operating characteristic curves, COMPUTED tomography, WHOLE body imaging, GYNECOLOGIC oncology, CANCER prognosis
Abstract

The article titled "OC04.03: Preoperative assessment of non-resectability in ovarian cancer according to ESGO criteria: a prospective multicentre study using imaging (ISAAC study)" presents the findings of a study conducted in five European gynecological oncology centers between 2018 and 2022. The study aimed to compare the effectiveness of abdominopelvic ultrasound, computed tomography (CT), and whole-body diffusion-weighted Magnetic Resonance Imaging (WB-DWI/MRI) in predicting surgical outcomes for patients with tubo-ovarian cancer. The results showed that ultrasound was non-inferior to CT and WB-DWI/MRI in predicting non-resectability when performed by experienced examiners. The study highlights the potential of ultrasound as a reliable imaging method for preoperative assessment in patients with tubo-ovarian cancer. [Extracted from the article]

Published
2024
Full Text
View/download PDF

17. OC04.01: Prediction of non‐resectability in ovarian cancer patients using peritoneal cancer index: a prospective multicentre study using imaging (ISAAC study).

Author

Pinto, P., Moro, F., Chiappa, V., Testa, A.C., Franchi, D., Alcazar, J., Frühauf, F., Burgetova, A., Mašek, M., Lambert, L., Altmanova, D., Arraiza, M., Avesani, G., Panico, C., Alessi, S., Pricolo, P., Vigorito, R., Calareso, G., Kocian, R., and Slama, J.

Subjects
DIFFUSION magnetic resonance imaging, COMPUTED tomography, WHOLE body imaging, PERITONEAL cancer, CANCER patients, NEOADJUVANT chemotherapy
Abstract

This article presents the findings of a European multicentric observational cohort study that aimed to evaluate the performance of the peritoneal cancer index (PCI) using different imaging methods in assessing peritoneal carcinomatosis and predicting non-resectability in advanced tubo-ovarian cancer patients. The study compared the use of ultrasound, computed tomography (CT), and whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) in calculating the PCI score. The results showed that ultrasound was non-inferior to CT in predicting non-resectability, and it was the best imaging method for determining preoperative PCI when performed by experienced examiners in dedicated oncological centers. [Extracted from the article]

Published
2024
Full Text
View/download PDF

18. Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations

Author

Ferrara, R, Lo Russo, G, Ciniselli, Cm, Gregorio, S, Calareso, G, Bassani, B, Proto, C, Prelaj, A, De Toma, A, Occhipinti, M, Brambilla, M, Manglaviti, S, Mazzeo, L, Beninato, T, Ganzinelli, M, De Braud, Fgm, Garassino, Mc, Colombo, Mp, Verderio, P, and Sangaletti, S

Published
2022

19. Re: MultiparametricMagnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study

Author

Necchi, A., Bandini, M., Calareso, G., Raggi, D., Pederzoli, F., Fare, E., Colecchia, M., Marandino, L., Bianchi, M., Gallina, A., Colombo, R., Fossati, N., Gandaglia, G., Capitanio, U., Deho, F., Giannatempo, P., Luciano, R., Salonia, A., Madison, R., Ali, S. M., Chung, J. H., Ross, J. S., Briganti, A., Montorsi, F., De Cobelli, F., and Messina, A.

Subjects
Male, Urethral Neoplasms, Urethra, Urology, Urinary Bladder, Humans, Penis
Published
2022

20. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients

Author

Massimino, M, Sunyach, M, Barretta, F, Gandola, L, Garegnani, A, Pecori, E, Spreafico, F, Bonneville-Levard, A, Meyronet, D, Mottolese, C, Boschetti, L, Biassoni, V, Schiavello, E, Giussani, C, Carrabba, G, Diletto, B, Pallotti, F, Stefini, R, Ferrari, A, Terenziani, M, Casanova, M, Luksch, R, Meazza, C, Podda, M, Chiaravalli, S, Puma, N, Bergamaschi, L, Morosi, C, Calareso, G, Giangaspero, F, Antonelli, M, Buttarelli, F, Frappaz, D, Massimino M., Sunyach M. P., Barretta F., Gandola L., Garegnani A., Pecori E., Spreafico F., Bonneville-Levard A., Meyronet D., Mottolese C., Boschetti L., Biassoni V., Schiavello E., Giussani C., Carrabba G., Diletto B., Pallotti F., Stefini R., Ferrari A., Terenziani M., Casanova M., Luksch R., Meazza C., Podda M., Chiaravalli S., Puma N., Bergamaschi L., Morosi C., Calareso G., Giangaspero F., Antonelli M., Buttarelli F. R., Frappaz D., Massimino, M, Sunyach, M, Barretta, F, Gandola, L, Garegnani, A, Pecori, E, Spreafico, F, Bonneville-Levard, A, Meyronet, D, Mottolese, C, Boschetti, L, Biassoni, V, Schiavello, E, Giussani, C, Carrabba, G, Diletto, B, Pallotti, F, Stefini, R, Ferrari, A, Terenziani, M, Casanova, M, Luksch, R, Meazza, C, Podda, M, Chiaravalli, S, Puma, N, Bergamaschi, L, Morosi, C, Calareso, G, Giangaspero, F, Antonelli, M, Buttarelli, F, Frappaz, D, Massimino M., Sunyach M. P., Barretta F., Gandola L., Garegnani A., Pecori E., Spreafico F., Bonneville-Levard A., Meyronet D., Mottolese C., Boschetti L., Biassoni V., Schiavello E., Giussani C., Carrabba G., Diletto B., Pallotti F., Stefini R., Ferrari A., Terenziani M., Casanova M., Luksch R., Meazza C., Podda M., Chiaravalli S., Puma N., Bergamaschi L., Morosi C., Calareso G., Giangaspero F., Antonelli M., Buttarelli F. R., and Frappaz D.

Abstract

Introduction: Medulloblastoma is the most common malignant brain tumor in children, but accounts for only 1% of brain cancers in adults. For standard-risk pediatric medulloblastoma, current therapy includes craniospinal irradiation (CSI) at reduced doses (23.4 Gy) associated with chemotherapy. Whereas most same-stage adult patients are still given CSI at 36 Gy, with or without chemotherapy, we report here on our use of reduced-dose CSI associated with chemotherapy for older patients. Methods: We gathered non-metastatic patients over 18 years old (median age 28 years, range 18–48) with minimal or no residual disease after surgery, no negative histological subtypes, treated between 1996–2018 at the Centre Léon Bérard (Lyon) and the INT (Milano). A series of 54 children with similar tumors treated in Milano was used for comparison. Results: Forty-four adults were considered (median follow-up 101 months): 36 had 23.4 Gy of CSI, and 8 had 30.6 Gy, plus a boost to the posterior fossa/tumor bed; 43 had chemotherapy as all 54 children, who had a median 83-month follow-up. The PFS and OS were 82.2 ± 6.1% and 89 ± 5.2% at 5 years, and 78.5 ± 6.9% and 75.2 ± 7.8% at ten, not significantly different from those of the children. CSI doses higher than 23.4 Gy did not influence PFS. Female adult patients tended to have a better outcome than males. Conclusion: The results obtained in our combined series are comparable with, or even better than those obtained after high CSI doses, underscoring the need to reconsider this treatment in adults.

Published
2020

21. Neoadjuvant pembrolizumab may result in long-term outcome improvement in biomarker-unselected patients with Muscle-Invasive Bladder Cancer (MIBC): Updated results from PURE-01

Author

Nocera, L., primary, Moschini, M., additional, Raggi, D., additional, Marandino, L., additional, Colecchia, M., additional, Lucianò, R., additional, Gibb, E.A., additional, Ross, J.S., additional, Messina, A., additional, Calareso, G., additional, Gallina, A., additional, Dehò, F., additional, Briganti, A., additional, Montorsi, F., additional, and Necchi, A., additional

Published
2022
Full Text
View/download PDF

24. 1105P Predictive factors of adverse events onset in GEPNET patients treated with PRRT

Author

Scalorbi, F., primary, Argiroffi, G., additional, Lorenzoni, A., additional, Baccini, M., additional, Gherardini, L., additional, Fuoco, V., additional, Prinzi, N., additional, Pusceddu, S., additional, Calareso, G., additional, Garanzini, E., additional, Centonze, G., additional, Milione, M., additional, Chiesa, C., additional, Seregni, E., additional, and Maccauro, M., additional

Published
2021
Full Text
View/download PDF

25. 868P A phase II trial of induction chemotherapy (IC), photon-, proton- and carbon ion-based radiotherapy (RT) integration in locally advanced inoperable sinonasal epithelial tumors patients (pts)

Author

Bossi, P., primary, Resteghini, C., additional, Orlandi, E., additional, Nicolai, P., additional, Vischioni, B., additional, Castelnuovo, P., additional, Turri-Zanoni, M., additional, Ferrari, M., additional, Rampelli, V., additional, Facchinetti, N., additional, Gambazza, S., additional, Calareso, G., additional, Quattrone, P., additional, Ingargiola, R., additional, Cavallo, A., additional, Franceschini, M., additional, Tuzi, A., additional, Mariani, L., additional, and Licitra, L.F., additional

Published
2021
Full Text
View/download PDF

26. Immunometabolism of circulating neutrophils in hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) alone or in combination with platinum-based chemotherapy (PCT) in non-small cell lung cancer (NSCLC) patients (pts)

Author

Ferrara, R, Jachetti, E, Calareso, G, Brambilla, M, Lo Russo, G, Proto, C, Prelaj, A, Signorelli, D, Galli, G, De Toma, A, Occhipinti, M, Manglaviti, S, Labianca, A, Ganzinelli, M, Spano, Sm, Molino, G, Martinetti, A, Greco, Fg, Bini, M, Beninato, T, de Braud, F, Colombo, Mp, Garassino, Mc, and Sangaletti, S

Published
2021

27. OC-0642 A radiomics based prognostic model for patients with head and neck squamous cell carcinoma

Author

Keek, S., primary, Wesseling, F., additional, Woodruff, H., additional, van Timmeren, J., additional, Nauta, I., additional, Hoffmann, T., additional, Cavalieri, S., additional, Calareso, G., additional, Primakov, S., additional, Leijenaar, R., additional, Licitra, L., additional, Ravanelli, M., additional, Scheckenbach, K., additional, Poli, T., additional, Lanfranco, D., additional, Vergeer, M., additional, Leemans, R., additional, Brakenhoff, R., additional, Hoebers, F., additional, and Lambin, P., additional

Published
2021
Full Text
View/download PDF

28. 178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients

Author

Provenzano, L., Favali, M., Mazzeo, L., Spagnoletti, A., Giani, C., Calareso, G., Ruggirello, M., Greco, F.G., Vigorito, R., Occhipinti, M., Brambilla, M., Manglaviti, S., Proto, C., Lo Russo, G., Trovò, F., De Braud, F.G.M., Ganzinelli, M., Pedrocchi, A., Miskovic, V., and Prelaj, A.

Published
2023
Full Text
View/download PDF

29. 2368P Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial

Author

Giannatempo, P., Bottiglieri, A., Guadalupi, V., Marandino, L., Raggi, D., Stellato, M., Rametta, A., Baciarello, G., Sepe, P., Claps, M., Buti, S., Pipitone, S., Iacovelli, R., Calareso, G., Alessi, A., Cattaneo, L., Verzoni, E., Ortega, C., Procopio, G., and Necchi, A.

Published
2023
Full Text
View/download PDF

30. A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images

Author

Keek, S.A., Keek, S.A., Wesseling, F.W.R., Woodruff, H.C., van Timmeren, J.E., Nauta, I.H., Hoffmann, T.K., Cavalieri, S., Calareso, G., Primakov, S., Leijenaar, R.T.H., Licitra, L., Ravanelli, M., Scheckenbach, K., Poli, T., Lanfranco, D., Vergeer, M.R., Leemans, C.R., Brakenhoff, R.H., Hoebers, F.J.P., Lambin, P., Keek, S.A., Keek, S.A., Wesseling, F.W.R., Woodruff, H.C., van Timmeren, J.E., Nauta, I.H., Hoffmann, T.K., Cavalieri, S., Calareso, G., Primakov, S., Leijenaar, R.T.H., Licitra, L., Ravanelli, M., Scheckenbach, K., Poli, T., Lanfranco, D., Vergeer, M.R., Leemans, C.R., Brakenhoff, R.H., Hoebers, F.J.P., and Lambin, P.

Abstract

Simple Summary Patients that suffer from advanced head and neck cancer have a low average survival chance. Improving prognosis could improve this survival rate as it may help in clinical decision making. Radiomics features calculated from images of the tumour describe tumour size, shape, and pattern. These characteristics may be linked to patient survival, which is investigated in this paper. We combined radiomics features with other biomarkers of survival of 809 patients to make a prognosis before treatment. We then compared the predicted prognosis with the actual outcome to see how well our model performs. Our model was able to make three distinct risk groups of low-, medium-, and high-survival patients. With these findings, doctors may make a better judgement of treatment and follow-up per patient, which might improve clinical outcomes. Background: Locoregionally advanced head and neck squamous cell carcinoma (HNSCC) patients have high relapse and mortality rates. Imaging-based decision support may improve outcomes by optimising personalised treatment, and support patient risk stratification. We propose a multifactorial prognostic model including radiomics features to improve risk stratification for advanced HNSCC, compared to TNM eighth edition, the gold standard. Patient and methods: Data of 666 retrospective- and 143 prospective-stage III-IVA/B HNSCC patients were collected. A multivariable Cox proportional-hazards model was trained to predict overall survival (OS) using diagnostic CT-based radiomics features extracted from the primary tumour. Separate analyses were performed using TNM8, tumour volume, clinical and biological variables, and combinations thereof with radiomics features. Patient risk stratification in three groups was assessed through Kaplan-Meier (KM) curves. A log-rank test was performed for significance (p-value < 0.05). The prognostic accuracy was reported through the concordance index (CI). Results: A model combining an 11-feature rad

Published
2021

31. OC04.02: Prediction of non‐resectability in ovarian cancer using the predictive index value score: a prospective multicentre study using imaging (ISAAC study).

Author

Moro, F., Pinto, P., Chiappa, V., Testa, A., Alcazar, J., Franchi, D., Frühauf, F., Burgetova, A., Mašek, M., Lambert, L., Arraiza, M., Altmanova, D., Avesani, G., Panico, C., Alessi, S., Pricolo, P., Vigorito, R., Calareso, G., Roman, K., and Slama, J.

Subjects
DIFFUSION magnetic resonance imaging, RECEIVER operating characteristic curves, COMPUTED tomography, MAGNETIC resonance imaging, SMALL intestine, CONTRAST-enhanced magnetic resonance imaging
Abstract

This article discusses a study conducted in European gynecological oncology centers to evaluate the performance of different imaging methods in predicting non-resectability in patients with suspected tubo-ovarian cancer. The study used a laparoscopy-based scoring system called the Predictive Index Value (PIV) score, which assesses the presence of disease in six predefined intra-abdominal sites. The imaging methods evaluated were ultrasound (US), contrast-enhanced computed tomography (CT), and whole-body magnetic resonance imaging with diffusion-weighted sequence (WB-DWI/MRI). The results showed that all three imaging methods had similar performance in predicting non-resectable tumors, with US being a viable alternative to MRI or CT when performed by experienced examiners in dedicated oncological centers. [Extracted from the article]

Published
2024
Full Text
View/download PDF

33. PH-0043: Age related toxicity and outcome in oropharyngeal and nasoparyngeal cancer patients

Author

IvaldI, E., primary, Infante, G., additional, Facchinetti, N., additional, Bossi, P., additional, Iacovelli, N.A., additional, Cavallo, A., additional, Ingargiola, R., additional, Locati, L.D., additional, Bergamini, C., additional, Resteghini, C., additional, Licitra, L., additional, Platini, F., additional, Calareso, G., additional, Fallai, C., additional, and Orlandi, E., additional

Published
2020
Full Text
View/download PDF

34. PO-1577: Baseline MRI-radiomics can predict overall survival in non endemic nasopharyngeal cancer patients

Author

Orlandi, E., primary, Calareso, G., additional, Tenconi, C., additional, Rancati, T., additional, Iacovelli, N.A., additional, Cavallo, A., additional, Facchinetti, N., additional, Ingargiola, R., additional, Ivaldi, E., additional, Romanello, D.A., additional, Corino, V., additional, Valdagni, R., additional, Cavalieri, S., additional, Alfieri, S., additional, Licitra, L., additional, Pignoli, E., additional, Mainardi, L., additional, Fallai, C., additional, and Bologna, M., additional

Published
2020
Full Text
View/download PDF

35. PD-0543: An externally validated prognostic CT radiomics model for head and neck cancer patients

Author

Keek, S., primary, Sanduleanu, S., additional, Woodruff, H.C., additional, Wesseling, F., additional, Mattavelli, D., additional, Ravanelli, M., additional, Hoffman, T.K., additional, Scheckenbach, K., additional, Leemans, C.R., additional, De Graaf, P., additional, Terhaard, C., additional, Van de Kamer, J., additional, Van der Heijden, M., additional, Calareso, G., additional, Gazzani, E.S., additional, Licitra, L., additional, Hoebers, F., additional, Poli, T., additional, and Lambin, P., additional

Published
2020
Full Text
View/download PDF

37. 1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)

Author

Ferrara, R., primary, Facchinetti, F., additional, Calareso, G., additional, Kasraoui, I., additional, Signorelli, D., additional, Proto, C., additional, Prelaj, A., additional, Naltet, C., additional, Lavaud, P., additional, Desmaris, R., additional, Viscardi, G., additional, Galli, G., additional, De Toma, A., additional, Martinetti, A., additional, Barlesi, F., additional, Planchard, D., additional, Soria, J-C., additional, Garassino, M.C., additional, Besse, B., additional, and Lo Russo, G., additional

Published
2020
Full Text
View/download PDF

38. 773P Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: Safety and preliminary activity of the open-label, single-arm, phase II ARCADIA trial

Author

Marandino, L., primary, Raggi, D., additional, Giannatempo, P., additional, Calareso, G., additional, Alessi, A., additional, Colecchia, M., additional, Madison, R., additional, Ross, J.S., additional, and Necchi, A., additional

Published
2020
Full Text
View/download PDF

39. Interim results of PEANUT: An open-label, single-arm, phase 2 study evaluating pembrolizumab plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC)

Author

Necchi, A., primary, Raggi, D., additional, Bandini, M., additional, Farè, E., additional, Giannatempo, P., additional, Colecchia, M., additional, Pederzoli, F., additional, Gallina, A., additional, Marandino, L., additional, Calareso, G., additional, Madison, R., additional, Briganti, A., additional, Ross, J., additional, and Montorsi, F., additional

Published
2020
Full Text
View/download PDF

40. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle -invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study

Author

Necchi, A, Bandini, M, Calareso, G, Raggi, D, Pederzoli, F, Fare, E, Colecchia, M, Marandino, L, Bianchi, M, Gallina, A, Colombo, R, Fossati, N, Gandaglia, G, Capitanio, U, Deho', F, Giannatempo, P, Luciano, R, Salonia, A, Madison, R, Ali, Sm, Chung, Jh, Ross, Js, Briganti, A, Montorsi, F, De Cobelli, F, and Messina, A

Published
2020

41. P2.11B.03 Circulating Hallmarks of Hyperprogression in NSCLC upon 1st Line PD-(L)1 Inhibitors Alone or in Combination with Chemotherapy

Author

Ferrara, R., Torelli, T., Brambilla, M., Prelaj, A., Ciniselli, C.M., Piva, A., Bassani, B., Jachetti, E., Calareso, G., Duroni, V., Proto, C., Manglaviti, S., Mazzeo, L., Beninato, T., Ganzinelli, M., Bulotta, A., Verderio, P., Ricciuti, B., Bonini, C., Garassino, M.C., Colombo, M.P., Torri, V., Agnelli, L., Lo Russo, G., and Sangaletti, S.

Published
2024
Full Text
View/download PDF

42. APACHE: An open label, randomized, phase II study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with refractory germ cell tumours (GCT): Results from the expanded combination therapy cohort

Author

Farè, E., primary, Raggi, D., additional, Giannatempo, P., additional, Colecchia, M., additional, Calareso, G., additional, Ali, S.M., additional, Chung, J., additional, Ross, J.S., additional, and Necchi, A., additional

Published
2019
Full Text
View/download PDF

43. A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck

Author

Bossi, P., primary, Merlano, M.C., additional, Ghi, M.G., additional, Rinaldi, G., additional, Caponigro, F., additional, Morelli, F., additional, Airoldi, M., additional, Farnesi, A., additional, Cassano, A., additional, Ferrari, D., additional, Mirabile, A., additional, Tosoni, A., additional, Galizia, D., additional, Moretti, G., additional, Sponghini, A.P., additional, Calareso, G., additional, Vingiani, A., additional, Perrone, F., additional, Falletta, A., additional, and Licitra, L.F., additional

Published
2019
Full Text
View/download PDF

44. PV-0312 Distributed learning in radiomics to predict overall survival in head and neck cancer

Author

Bogowicz, M., primary, Jochems, A., additional, Huang, S.H., additional, Chan, B., additional, Waldron, J.N., additional, O'Sullivan, B., additional, Tanadini-Lang, S., additional, Riesterer, O., additional, Studer, G., additional, Unkelbach, J., additional, Brakenhoff, R.H., additional, Nauta, I., additional, Gazzani, S.E., additional, Calareso, G., additional, Scheckenbach, K., additional, Hoebers, F., additional, Barakat, S., additional, Keek, S., additional, Sanduleanu, S., additional, Vergeer, M., additional, Leemans, R.C., additional, Terhaard, C.H., additional, Van den Brekel, M.W., additional, Guckenberger, M., additional, and Lambin, P., additional

Published
2019
Full Text
View/download PDF

45. PO-165 Phase 2 study on axitinib in recurrent/metastatic salivary gland cancer of upper aerodigestive tract

Author

Locati, L.D., primary, Cavalieri, S., additional, Bergamini, C., additional, Resteghini, C., additional, Alfieri, S., additional, Calareso, G., additional, Bossi, P., additional, Quattrone, P., additional, Granata, R., additional, Galbiati, D., additional, Platini, F., additional, Orlandi, E., additional, Mariani, L., additional, and Licitra, L., additional

Published
2019
Full Text
View/download PDF

47. PO-160 Tumor and retropharyngeal nodal GTVs prognostic role in unresectable non-glandular sinonasal cancers

Author

Ferella, L., primary, Cavallo, A., additional, Miceli, R., additional, lacovelli, N.A., additional, Giandini, T., additional, Pignoli, E., additional, Calareso, G., additional, Bossi, P., additional, Gravina, G.L., additional, Nicolai, P., additional, Castelnuovo, P., additional, Piazza, C., additional, Licitra, L., additional, Fallai, C., additional, and Orlandi, E., additional

Published
2019
Full Text
View/download PDF

50. Genomics features (GF) and integration with MRI radiomics features (RF) to develop a prognostic model in oral cavity squamous cell carcinoma (OSCC)

Author

Cavalieri, S., primary, De Cecco, L., additional, Calareso, G., additional, Silva, M., additional, Gazzani, S.E., additional, Bologna, M., additional, Nauta, I., additional, Wesseling, F., additional, Lopez Perez, L., additional, Shefi, R., additional, Tountopoulos, V., additional, Fico, G., additional, Scheckenbach, K., additional, Brakenhoff, R.H., additional, Hoebers, F., additional, Canevari, S., additional, Poli, T., additional, Licitra, L., additional, and Mainardi, L., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results